April 5, 2022
The University of Cincinnati's Dr. Hyacinth I. Hyacinth is researching how different rates of cerebral small vessel disease and genetic differences contribute to higher rates of Alzheimer's disease and related dementias in non-Hispanic Black populations compared to non-Hispanic white patients.
June 6, 2022
The University of Cincinnati's Atsuo Sasaki and an international team of collaborators have been awarded a Human Frontier Science Program research grant to learn more about how cells migrate, with an ultimate goal of developing new treatments to prevent cancer growth and spread.
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
October 6, 2022
U.S. News & World Report highlighted recent research from the University of Cincinnati that supports the hypothesis that Alzheimer’s disease is caused by a decline in levels of a protein called amyloid-beta.
April 3, 2023
University of Cincinnati researchers recently published findings in the journal Cancer that found several enriched species, associated with enhanced tumor immune response, in the microbiomes of long-term pancreatic cancer survivors.
April 21, 2023
The University of Cincinnati's Alberto Espay will present Parkinson's disease research at the American Academy of Neurology's annual meeting April 22-27 in Boston.
October 4, 2022
University of Cincinnati researchers led by Alberto Espay and Andrea Sturchio published new research that supports the hypothesis that Alzheimer’s disease is caused by a decline in levels of a protein called amyloid-beta.
November 15, 2022
The University of Cincinnati's Jeffrey Strawn led research that found in utero exposure to certain flame retardant chemicals may be a risk factor for developing anxiety symptoms in early adolescence.
October 25, 2022
National media outlets highlighted the results of the first-in-human trial of FLASH radiotherapy, led by University of Cincinnati Cancer Center researchers.
March 21, 2023
Amanda Jackson, MD, is the site principal investigator at the University of Cincinnati for the UP-NEXT trial that is testing a new treatment for a subset of ovarian cancer patients.